Conditions: Ovarian Cancer Fallopian Tube Cancer Primary Peritoneal Carcinoma Uterine Cancer
Keywords: Ovarian Cancer Fallopian Tube Cancer Primary Peritoneal Carcinoma Uterine Cancer Intraperitoneal Chemotherapy IP Chemotherapy Gynecologic Cancer Women's Cancer Cisplatin Paclitaxel Recurrent Platinum Sensitive Ovarian Cancer
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 21
Healthy volunteers: no

Brief summary:
The purpose of this study is to evaluate giving chemotherapy drugs directly into the abdomen (belly) along with intravenous administration.

Detailed description:
Giving chemotherapy directly into the abdomen is called intraperitoneal (IP) chemotherapy. Because ovarian, fallopian, primary peritoneal and uterine cancer spread in the abdominal cavity, giving chemotherapy drugs by infusion into the abdominal cavity may result in a greater dose of the drugs reaching the tumor cells. Intraperitoneal treatments will be administered through an implantable peritoneal catheter. These catheters are to be inserted into the peritoneal cavity, tunneled through the subcutaneous tissue, and connected to an implantable port, which is placed in the subcutaneous tissue of the anterior, inferior thorax.

Arms:
arm 1: There is only one arm for this study and it represents the participants receiving the intraperitoneal chemotherapy

Interventions: intervention 1: Paclitaxel, Cisplatin IP
Intervention descriptions: intervention 1: Paclitaxel 135 mg/m2 IV (3-hr infusion) on Day 1, Cisplatin 50 mg/m2 IP on Days 1 and 8, Repeat every 3 weeks for 6 cycles

Protocol document: